PHASE 2 EFFICACY AND SAFETY OF AUTOLOGOUS TUMOR-INFILTRATING LYMPHOCYTE (TIL) CELL THERAPY IN COMBINATION WITH PEMBROLIZUMAB IN IMMUNE CHECKPOINT INHIBITOR-NAIVE PATIENTS WITH ADVANCED CANCERS

被引：20

作者：

O'Malley, David ^{[1
]}

Lee, Sylvia ^{[2
]}

Psyrri, Amanda ^{[3
]}

Sukari, Ammar ^{[4
]}

Thomas, Sajeve ^{[5
]}

Wenham, Robert ^{[6
]}

Gogas, Helen ^{[7
]}

Jazaeri, Amir ^{[8
]}

Monk, Bradley ^{[9
]}

Rose, Peter ^{[10
]}

Reuda, Antonio ^{[11
]}

Finckenstein, Friedrich Graf ^{[12
]}

Jagasia, Madan ^{[12
]}

Fiaz, Rana ^{[12
]}

Garelik, Brigid ^{[12
]}

Shi, Wen ^{[12
]}

Desai, Anjali ^{[12
]}

Sulur, Giri ^{[12
]}

Chen, Guang ^{[12
]}

Wu, Xiao ^{[12
]}

Jimeno, Antonio ^{[13
]}

机构：

[1] Ohio State Univ, Columbus, OH 43210 USA

[2] Fred Hutchinson Canc Ctr, Seattle, WA USA

[3] Attikon Univ, Gen Hosp, Athens, Greece

[4] Karmanos Canc Inst, Detroit, MI USA

[5] Orlando Hlth Canc Inst, Orlando, FL USA

[6] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[7] Natl & Kapodistrian Univ Athen, Athens, Greece

[8] MD Anderson Canc Ctr, Houston, TX USA

[9] US Oncol Network, Arizona Oncol, Phoenix, AZ USA

[10] Cleveland Clin, Columbud, OH USA

[11] Hosp Reg Univ Malag, Malaga, Spain

[12] Iovance Biotherapeut Inc, San Carlos, CA USA

[13] Univ Colorado, Sch Med, Aurora, CO USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷

关键词：

D O I：

10.1136/jitc-2021-SITC2021.492

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

492

引用

页码：A523 / A524

页数：2

共 50 条

[41] Immune checkpoint inhibitor combination therapy leads to more nephrotoxicity in advanced renal cell carcinoma patients
Song, Yuxuan
Han, Songchen
Xu, Tao
WORLD JOURNAL OF UROLOGY, 2023, 41 (07) : 1991 - 1992
[42] Immune checkpoint inhibitor combination therapy leads to more nephrotoxicity in advanced renal cell carcinoma patients
Yuxuan Song
Songchen Han
Tao Xu
World Journal of Urology, 2023, 41 : 1991 - 1992
[43] Managing Immune-Related Adverse Events (irAEs) During Tumor Infiltrating Lymphocyte (TIL) Therapy: Insights from a Case of Refractory Immune Checkpoint Inhibitor (ICI)-Induced Gastritis
Darwin, Alicia H.
Kim, Karen C.
Kirane, Amanda R.
Funchain, Pauline
Warner, Allison Betof
CANCER IMMUNOLOGY RESEARCH, 2025, 13 (02)
[44] An investigator-initiated phase I study to assess the safety and tolerability of ex vivo next-generation neoantigen-selected tumor-infiltrating lymphocyte (TIL) therapy in advanced immune checkpoint blockade (ICB) resistant solid tumors (NEXTGENTIL-ACT)
Galvao, V.
Palomero, J.
Creus-Gonzalez, I.
Lostes Bardaji, M. J.
Lozano-Rabella, M.
Garcia-Garijo, A.
Yuste, A.
Rodriguez, L.
Villalobos Alberu, X.
Rotxes, M.
Vieito Villar, M.
Santa Gadea, O. Saavedra
Alonso, G.
Brana, I.
Munoz-Couselo, E.
Querol, S.
Tabernero, J.
Martin-Lluesma, S.
Gros, A.
Garralda, E.
ANNALS OF ONCOLOGY, 2023, 34 : S650 - S650
[45] Efficacy and safety of a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer alone and in combination with immune checkpoint inhibitors
Williams, William
Dakhil, Shaker R.
Holmes, Jarrod P.
Bhattacharya, Saveri
Calfa, Carmen
Kundra, Ajay
Adams, Daniel L.
DaSilva, Diane
Peoples, George E.
Sunkari, Vivek
Lacher, Markus
Wiseman, Charles L.
CANCER RESEARCH, 2020, 80 (04)
[46] DELTA-2: A PHASE 1, OPEN-LABEL, MULTICENTER STUDY OF ITIL-168, AN AUTOLOGOUS TUMORINFILTRATING LYMPHOCYTE (TIL) CELL THERAPY, WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
Yeku, Oladapo
Olson, Daniel
Ward, Jeffrey
Patel, Sandip
Aycock, Jeff
Donahue, Amber
Jiang, Yizhou
Le Gall, John
Roberts, Zachary
Alvarez-Rodriguez, Ruben
Seng, Judy
Shen, Tong
Kothari, Nishi
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A813 - A813
[47] Characterization of the Transcriptomic and T-Cell Receptor (TCR) Clonal Heterogeneity of Tumor-Infiltrating Lymphocyte (TIL) Therapy Infusion Products by Single-Cell Sequencing and Correlative Analyses With Clinical Efficacy in Patients with Advanced Cutaneous Melanoma
Yuan, Jinzhou
Kueberuwa, Gray
Jiang, Yizhou
Bao, Leyuan
Le Brocq, Michelle
Sharpe, Catherine
Bridgeman, John S.
Guest, Ryan D.
Roberts, Zachary J.
Hawkins, Robert E.
Robbins, Paul B.
Alvarez-Rodriguez, Ruben
MOLECULAR THERAPY, 2022, 30 (04) : 400 - 401
[48] Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients
Radvanyi, Laszlo G.
Bernatchez, Chantale
Zhang, Minying
Fox, Patricia S.
Miller, Priscilla
Chacon, Jessica
Wu, Richard
Lizee, Gregory
Mahoney, Sandy
Alvarado, Gladys
Glass, Michelle
Johnson, Valen E.
McMannis, John D.
Shpall, Elizabeth
Prieto, Victor
Papadopoulos, Nicholas
Kim, Kevin
Homsi, Jade
Bedikian, Agop
Hwu, Wen-Jen
Patel, Sapna
Ross, Merrick I.
Lee, Jeffrey E.
Gershenwald, Jeffrey E.
Lucci, Anthony
Royal, Richard
Cormier, Janice N.
Davies, Michael A.
Mansaray, Rahmatu
Fulbright, Orenthial J.
Toth, Christopher
Ramachandran, Renjith
Wardell, Seth
Gonzalez, Audrey
Hwu, Patrick
CLINICAL CANCER RESEARCH, 2012, 18 (24) : 6758 - 6770
[49] Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma
Ishihara, Hiroki
Nemoto, Yuki
Nakamura, Kazutaka
Tachibana, Hidekazu
Fukuda, Hironori
Yoshida, Kazuhiko
Kobayashi, Hirohito
Iizuka, Junpei
Shimmura, Hiroaki
Hashimoto, Yasunobu
Kondo, Tsunenori
Takagi, Toshio
TARGETED ONCOLOGY, 2023, 18 (01) : 159 - 168
[50] Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma
Hiroki Ishihara
Yuki Nemoto
Kazutaka Nakamura
Hidekazu Tachibana
Hironori Fukuda
Kazuhiko Yoshida
Hirohito Kobayashi
Junpei Iizuka
Hiroaki Shimmura
Yasunobu Hashimoto
Tsunenori Kondo
Toshio Takagi
Targeted Oncology, 2023, 18 : 159 - 168

← 1 2 3 4 5 →